Lianxi Song

机构：Hunan City University, Yantai Laiyang Central Hospital

发表论文 29 篇 · 总被引 148 次 · h-index 8

代表论文

• Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer (2022 · Communications Medicine · 被引 20)
• Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study (2022 · BMC Cancer · 被引 20)
• Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study (2023 · BMC Cancer · 被引 19)
• Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China (2024 · Cancer Immunology Immunotherapy · 被引 16)
• Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib (2022 · Lung Cancer · 被引 10)
• First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (2024 · Med · 被引 9)